Download PDF
Semin Plast Surg 2021; 35(03): 216-222
DOI: 10.1055/s-0041-1731631
Review Article

Dupuytren's Disease: An Outcomes-Focused Update

Yasser H. Almadani
1   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Quebec, Canada
,
Joshua Vorstenbosch
1   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Quebec, Canada
,
Johnny Ionut Efanov
2   Division of Plastic and Reconstructive Surgery, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
,
Liqin Xu
1   Division of Plastic and Reconstructive Surgery, McGill University Health Centre, Montreal, Quebec, Canada
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Dupuytren's disease (DD) remains a common fibroproliferative condition with significant sequelae and impact on patient's lives. The etiology of DD is poorly understood, and genetic predisposition is thought to be a strongly associated factor. Despite remarkable strides in improving our molecular understanding of DD, clinical treatment options have not yet overcome the frequently encountered challenge of recurrence. Recurrence rates continue to shape the prognosis of this fibrotic condition. In this outcomes-focused article, the various treatment modalities are reviewed. This further emphasizes the importance of patient education and providing them with the information to make informed decisions about their treatment.

Keywords

Dupuytren's disease - collagenase injection - needle aponeurotomy - open fasciectomy


Publication History

Article published online:
06 July 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Grazina R, Teixeira S, Ramos R, Sousa H, Ferreira A, Lemos R. Dupuytren's disease: where do we stand?. EFORT Open Rev 2019; 4 (02) 63-69
    CrossrefPubMedGoogle Scholar
  • 2 Lurati AR. Dupuytren's contracture. Workplace Health Saf 2017; 65 (03) 96-99
    CrossrefPubMedGoogle Scholar
  • 3 Shaw Jr RB, Chong AKS, Zhang A, Hentz VR, Chang J. Dupuytren's disease: history, diagnosis, and treatment. Plast Reconstr Surg 2007; 120 (03) 44e-54e
    CrossrefPubMedGoogle Scholar
  • 4 Lanting R, Broekstra DC, Werker PMN, van den Heuvel ER. A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries. Plast Reconstr Surg 2014; 133 (03) 593-603
    CrossrefPubMedGoogle Scholar
  • 5 Whaley DC, Elliot D. Dupuytren's disease: a legacy of the north?. J Hand Surg [Br] 1993; 18 (03) 363-367
    CrossrefPubMedGoogle Scholar
  • 6 Khashan M, Smitham PJ, Khan WS, Goddard NJ. Dupuytren's disease: review of the current literature. Open Orthop J 2011; 5 (Suppl. 02) 283-288
    CrossrefPubMedGoogle Scholar
  • 7 Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. Prevalence, incidence, and treatments of Dupuytren's disease in the United States: results from a population-based study. Hand (N Y) 2011; 6 (02) 149-158
    CrossrefPubMedGoogle Scholar
  • 8 Mansur HG, Oliveira ER, Gonçalves CB. Epidemiological analysis of patients with Dupuytren's disease. Rev Bras Ortop 2017; 53 (01) 10-14
    PubMedGoogle Scholar
  • 9 Gudmundsson KG, Arngrímsson R, Sigfússon N, Björnsson A, Jónsson T. Epidemiology of Dupuytren's disease: clinical, serological, and social assessment. The Reykjavik Study. J Clin Epidemiol 2000; 53 (03) 291-296
    CrossrefPubMedGoogle Scholar
  • 10 Larsen S, Krogsgaard DG, Aagaard Larsen L, Iachina M, Skytthe A, Frederiksen H. Genetic and environmental influences in Dupuytren's disease: a study of 30,330 Danish twin pairs. J Hand Surg Eur Vol 2015; 40 (02) 171-176
    CrossrefPubMedGoogle Scholar
  • 11 Riesmeijer SA, Werker PMN, Nolte IM. Ethnic differences in prevalence of Dupuytren disease can partly be explained by known genetic risk variants. Eur J Hum Genet 2019; 27 (12) 1876-1884
    CrossrefPubMedGoogle Scholar
  • 12 Geoghegan JM, Forbes J, Clark DI, Smith C, Hubbard R. Dupuytren's disease risk factors. J Hand Surg [Br] 2004; 29 (05) 423-426
    CrossrefPubMedGoogle Scholar
  • 13 Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and the risk of Dupuytren's contracture. J Bone Joint Surg Br 1997; 79 (02) 206-210
    CrossrefPubMedGoogle Scholar
  • 14 Elliot D, Ragoowansi R. Dupuytren's disease secondary to acute injury, infection or operation distal to the elbow in the ipsilateral upper limb--a historical review. J Hand Surg [Br] 2005; 30 (02) 148-156
    CrossrefPubMedGoogle Scholar
  • 15 Picardo NE, Khan WS. Advances in the understanding of the aetiology of Dupuytren's disease. Surgeon 2012; 10 (03) 151-158
    CrossrefPubMedGoogle Scholar
  • 16 Liss GM, Stock SR. Can Dupuytren's contracture be work-related?: review of the evidence. Am J Ind Med 1996; 29 (05) 521-532
    CrossrefPubMedGoogle Scholar
  • 17 Murrell GA. An insight into Dupuytren's contracture. Ann R Coll Surg Engl 1992; 74 (03) 156-160 , discussion 161
    PubMedGoogle Scholar
  • 18 Gabbiani G, Majno G. Dupuytren's contracture: fibroblast contraction? An ultrastructural study. Am J Pathol 1972; 66 (01) 131-146
    PubMedGoogle Scholar
  • 19 Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002; 3 (05) 349-363
    CrossrefPubMedGoogle Scholar
  • 20 Krause C, Kloen P, Ten Dijke P. Elevated transforming growth factor β and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts. Fibrogenesis Tissue Repair 2011; 4 (01) 14
    CrossrefPubMedGoogle Scholar
  • 21 Vi L, Gan BS, O'Gorman DB. The potential roles of cell migration and extra-cellular matrix interactions in Dupuytren's disease progression and recurrence. Med Hypotheses 2010; 74 (03) 510-512
    CrossrefPubMedGoogle Scholar
  • 22 Luck JV. Dupuytren's contracture; a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg Am 1959; 41-A (04) 635-664
    CrossrefPubMedGoogle Scholar
  • 23 Krause C, Kloen P. Concurrent inhibition of TGF-β and mitogen driven signaling cascades in Dupuytren's disease - non-surgical treatment strategies from a signaling point of view. Med Hypotheses 2012; 78 (03) 385-388
    CrossrefPubMedGoogle Scholar
  • 24 Ikushima H, Miyazono K. TGF-β signal transduction spreading to a wider field: a broad variety of mechanisms for context-dependent effects of TGF-β. Cell Tissue Res 2012; 347 (01) 37-49
    CrossrefPubMedGoogle Scholar
  • 25 Santibañez JF, Quintanilla M, Bernabeu C. TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. Clin Sci (Lond) 2011; 121 (06) 233-251
    CrossrefPubMedGoogle Scholar
  • 26 Denkler KA, Vaughn CJ, Dolan EL, Hansen SL. Evidence-based medicine: options for Dupuytren's contracture: incise, excise, and dissolve. Plast Reconstr Surg 2017; 139 (01) 240e-255e
    CrossrefPubMedGoogle Scholar
  • 27 Milner RH. Dupuytren's disease affecting the thumb and first web of the hand. J Hand Surg [Br] 2003; 28 (01) 33-36
    CrossrefPubMedGoogle Scholar
  • 28 Barton NJ. Dupuytren's disease arising from the abductor digiti minimi. J Hand Surg [Br] 1984; 9 (03) 265-270
    CrossrefPubMedGoogle Scholar
  • 29 Meathrel KE, Thoma A. Abductor digiti minimi involvement in Dupuytren's contracture of the small finger. J Hand Surg Am 2004; 29 (03) 510-513
    CrossrefPubMedGoogle Scholar
  • 30 Hindocha S, Stanley JK, Watson JS, Bayat A. Revised Tubiana's staging system for assessment of disease severity in Dupuytren's disease-preliminary clinical findings. Hand (N Y) 2008; 3 (02) 80-86
    CrossrefPubMedGoogle Scholar
  • 31 Hueston JT. Recurrent Dupuytren's contracture. Plast Reconstr Surg 1963; 31 (01) 66-69
    CrossrefPubMedGoogle Scholar
  • 32 Young JR, Sternbach S, Willinger M, Hutchinson ID, Rosenbaum AJ. The etiology, evaluation, and management of plantar fibromatosis. Orthop Res Rev 2018; 11: 1-7
    PubMedGoogle Scholar
  • 33 Bogdanov I, Rowland Payne C. Dupuytren contracture as a sign of systemic disease. Clin Dermatol 2019; 37 (06) 675-678
    CrossrefPubMedGoogle Scholar
  • 34 Gaffney CD, Kashanian JA. Peyronie disease. JAMA 2020; 324 (24) 2566
    CrossrefPubMedGoogle Scholar
  • 35 Hindocha S. Risk factors, disease associations, and Dupuytren diathesis. Hand Clin 2018; 34 (03) 307-314
    CrossrefPubMedGoogle Scholar
  • 36 Hindocha S, Stanley JK, Watson S, Bayat A. Dupuytren's diathesis revisited: evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg Am 2006; 31 (10) 1626-1634
    CrossrefPubMedGoogle Scholar
  • 37 Smith SP, Devaraj VS, Bunker TD. The association between frozen shoulder and Dupuytren's disease. J Shoulder Elbow Surg 2001; 10 (02) 149-151
    CrossrefPubMedGoogle Scholar
  • 38 Alser OH, Kuo RYL, Furniss D. Nongenetic factors associated with Dupuytren's disease: a systematic review. Plast Reconstr Surg 2020; 146 (04) 799-807
    CrossrefPubMedGoogle Scholar
  • 39 Christie WS, Puhl AA, Lucaciu OC. Cross-frictional therapy and stretching for the treatment of palmar adhesions due to Dupuytren's contracture: a prospective case study. Man Ther 2012; 17 (05) 479-482
    CrossrefPubMedGoogle Scholar
  • 40 Larocerie-Salgado J, Davidson J. Nonoperative treatment of PIPJ flexion contractures associated with Dupuytren's disease. J Hand Surg Eur Vol 2012; 37 (08) 722-727
    CrossrefPubMedGoogle Scholar
  • 41 Sweet S, Blackmore S. Surgical and therapy update on the management of Dupuytren's disease. J Hand Ther 2014; 27 (02) 77-83 , quiz 84
    CrossrefPubMedGoogle Scholar
  • 42 Desai SS, Hentz VR. Collagenase clostridium histolyticum for Dupuytren's contracture. Expert Opin Biol Ther 2010; 10 (09) 1395-1404
    CrossrefPubMedGoogle Scholar
  • 43 Hurst LC, Badalamente MA, Hentz VR. et al; CORD I Study Group. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009; 361 (10) 968-979
    CrossrefPubMedGoogle Scholar
  • 44 Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am 2010; 35 (12) 2027-38.e1
    CrossrefPubMedGoogle Scholar
  • 45 Zhou C, Hovius SER, Slijper HP. et al. Collagenase clostridium histolyticum versus limited fasciectomy for Dupuytren's contracture: outcomes from a multicenter propensity score matched study. Plast Reconstr Surg 2015; 136 (01) 87-97
    CrossrefPubMedGoogle Scholar
  • 46 Peimer CA, Wilbrand S, Gerber RA, Chapman D, Szczypa PP. Safety and tolerability of collagenase clostridium histolyticum and fasciectomy for Dupuytren's contracture. J Hand Surg Eur Vol 2015; 40 (02) 141-149
    CrossrefPubMedGoogle Scholar
  • 47 Zhang D, Earp BE, Benavent KA, Blazar P. Collagenase treatment of Dupuytren's disease with minimum 5-year follow-up: recurrence, reintervention, and satisfaction. Plast Reconstr Surg 2020; 146 (05) 1071-1079
    CrossrefPubMedGoogle Scholar
  • 48 Peimer CA, Blazar P, Coleman S, Kaplan FT, Smith T, Lindau T. Dupuytren contracture recurrence following treatment with collagenase clostridium histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-year data. J Hand Surg Am 2015; 40 (08) 1597-1605
    CrossrefPubMedGoogle Scholar
  • 49 Cook J, Waughtel J, Andreoni AR, Sakharpe A, Friedman DW. Collagenase clostridium histolyticum for Dupuytren's contracture: comparing single and concurrent injections. Plast Reconstr Surg 2019; 143 (04) 782e-787e
    CrossrefPubMedGoogle Scholar
  • 50 Foucher G, Cornil C, Lenoble E. Open palm technique for Dupuytren's disease. A five-year follow-up. Ann Chir Main Memb Super 1992; 11 (05) 362-366
    PubMedGoogle Scholar
  • 51 Eaton C. Percutaneous fasciotomy for Dupuytren's contracture. J Hand Surg Am 2011; 36 (05) 910-915
    CrossrefPubMedGoogle Scholar
  • 52 Pess GM, Pess RM, Pess RA. Results of needle aponeurotomy for Dupuytren contracture in over 1,000 fingers. J Hand Surg Am 2012; 37 (04) 651-656
    CrossrefPubMedGoogle Scholar
  • 53 Becker GW, Davis TR. The outcome of surgical treatments for primary Dupuytren's disease--a systematic review. J Hand Surg Eur Vol 2010; 35 (08) 623-626
    CrossrefPubMedGoogle Scholar
  • 54 Baltzer H, Binhammer PA. Cost-effectiveness in the management of Dupuytren's contracture. A Canadian cost-utility analysis of current and future management strategies. Bone Joint J 2013; 95-B (08) 1094-1100
    CrossrefPubMedGoogle Scholar
  • 55 Morhart M. Pearls and pitfalls of needle aponeurotomy in Dupuytren's disease. Plast Reconstr Surg 2015; 135 (03) 817-825
    CrossrefPubMedGoogle Scholar
  • 56 Selles RW, Zhou C, Kan HJ, Wouters RM, van Nieuwenhoven CA, Hovius SER. Percutaneous aponeurotomy and lipofilling versus limited fasciectomy for Dupuytren's contracture: 5-year results from a randomized clinical trial. Plast Reconstr Surg 2018; 142 (06) 1523-1531
    CrossrefPubMedGoogle Scholar
  • 57 Coert JH, Nérin JP, Meek MF. Results of partial fasciectomy for Dupuytren disease in 261 consecutive patients. Ann Plast Surg 2006; 57 (01) 13-17
    CrossrefPubMedGoogle Scholar
  • 58 Denkler K. Dupuytren's fasciectomies in 60 consecutive digits using lidocaine with epinephrine and no tourniquet. Plast Reconstr Surg 2005; 115 (03) 802-810
    CrossrefPubMedGoogle Scholar
  • 59 Denkler K. Surgical complications associated with fasciectomy for Dupuytren's disease: a 20-year review of the English literature. Eplasty 2010; 10: e15
    PubMedGoogle Scholar
  • 60 McCash CR. The open palm technique in Dupuytren's contracture. Br J Plast Surg 1964; 17: 271-280
    CrossrefPubMedGoogle Scholar
  • 61 Lesiak AC, Jarrett NJ, Imbriglia JE. Modified McCash technique for management of Dupuytren contracture. J Hand Surg Am 2017; 42 (05) 395.e1-395.e5
    CrossrefPubMedGoogle Scholar
  • 62 Lesiak AC, Jarrett NJ, Imbriglia JE. Modified McCash technique for management of dupuytren contracture. J Hand Surg Am 2017; 42 (05) 395.e1-395.e5 ; Available from: https://pubmed.ncbi.nlm.nih.gov/28259564/
    CrossrefPubMedGoogle Scholar
  • 63 Watson JD. Fasciotomy and Z-plasty in the management of Dupuytren's contracture. Br J Plast Surg 1984; 37 (01) 27-30
    CrossrefPubMedGoogle Scholar
  • 64 Citron ND, Nunez V. Recurrence after surgery for Dupuytren's disease: a randomized trial of two skin incisions. J Hand Surg [Br] 2005; 30 (06) 563-566
    CrossrefPubMedGoogle Scholar
  • 65 Chen NC, Srinivasan RC, Shauver MJ, Chung KC. A systematic review of outcomes of fasciotomy, aponeurotomy, and collagenase treatments for Dupuytren's contracture. Hand (N Y) 2011; 6 (03) 250-255
    CrossrefPubMedGoogle Scholar
  • 66 Noureddine H, Vejsbjerg K, Harrop JE, White MJ, Chakravarthy J, Harrison JWK. Fasciectomy under local anaesthetic and adrenaline for Dupuytren's contracture in a community setting in the UK with a cost analysis. Bone Joint J 2020; 102-B (10) 1354-1358
    CrossrefPubMedGoogle Scholar
  • 67 van Rijssen AL, Ter Linden H, Werker PMN. Five-year results of a randomized clinical trial on treatment in Dupuytren's disease: percutaneous needle fasciotomy versus limited fasciectomy. Plast Reconstr Surg 2012; 129 (02) 469-477
    CrossrefPubMedGoogle Scholar
  • 68 Zhou C, Hovius SER, Slijper HP. et al. Comparative Effectiveness of Collagenase Injection for Dupuytren Contracture, in Dupuytren Disease and Related Diseases-The Cutting Edge. Springer; 2017: 259-270
    CrossrefGoogle Scholar
  • 69 Yoon AP, Kane RL, Hutton DW, Chung KC. Cost-effectiveness of recurrent Dupuytren contracture treatment. JAMA Netw Open 2020; 3 (10) e2019861-e2019861
    CrossrefPubMedGoogle Scholar